Prevalence of HCV in beta-thalassemia major patients visiting tertiary care hospitals in Lahore - Pakistan

被引:0
作者
Nazir, Shahid [1 ]
Faraz, Ahmad [1 ]
Shahzad, Naeem [2 ]
Ali, Nasir [3 ]
Khan, Muhammd Arman [4 ]
Iqbal, Mazhar [2 ]
Khan, Muhammad Farhan [4 ]
Ahmed, Toraiz [5 ]
Rakha, Allah [6 ]
Sabzwari, Javed [2 ]
机构
[1] Ittefaq Hosp Trust, Dept Pathol, Lahore, Pakistan
[2] Sheikh Zaid Med Complex, Dept Biochem, Lahore, Pakistan
[3] Univ Fed Parana, Curitiba, Parana, Brazil
[4] Univ Vet & Anim Sci, Inst Biochem & Biotechnol, Lahore, Pakistan
[5] Univ Vet & Anim Sci, Dept Epidemiol, Lahore, Pakistan
[6] Univ Hlth Sci, Lahore, Pakistan
关键词
Prevalence; HCV; Thalassemia; Transfusion Transmitted Infection;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Post-transfusion hepatitis (PTH) is majorly caused by hepatitis C virus (HCV). So, recipients of blood/blood products, post-transfusion hepatitis (PTH), renal dialysis patients and intravenous drug users all represent high-risk groups for infection. The aim of the present research was to determine the prevalence of HCV antibody in beta-thalassemia major patients visiting different tertiary care hospital in Lahore, Pakistan. Methods: HCV seroprevalence and risk factors were studied in 200 beta-thalassemia major patients (24 females, 176 males) with different age groups by second generation ELISA during January 2013 to May 2013. Confirmed beta-thalassemia major patients from three different tertiary care hospitals were selected with special reference to age, age at the time of diagnosis, frequency of transfusion and present clinical status. Results: Among 200 patients, 82 (41%) were found reactive for HCV antibody with age range of 2 to 18 years with mean age of 8.5 years. Conclusion: This study showed that hemodialysis patients and beta-thalassemia sufferers were at higher risk of having HCV infection; the prevalence being 41%.
引用
收藏
页码:197 / 201
页数:5
相关论文
共 13 条
[1]   SEXUAL TRANSMISSION OF HEPATITIS-C VIRUS [J].
BRESTERS, D ;
MAUSERBUNSCHOTEN, EP ;
REESINK, HW ;
ROOSENDAAL, G ;
VANDERPOEL, CL ;
CHAMULEAU, RAFM ;
JANSEN, PLM ;
WEEGINK, CJ ;
CUYPERS, HTM ;
LELIE, PN ;
VANDENBERG, HM .
LANCET, 1993, 342 (8865) :210-211
[2]   Complications of β-thalassemia major in north America [J].
Cunningham, MJ ;
Macklin, EA ;
Neufeld, EJ ;
Cohen, AR .
BLOOD, 2004, 104 (01) :34-39
[3]  
Greenberg P L, 2001, Hematology Am Soc Hematol Educ Program, P479
[4]   INCREASED DETECTION OF HEPATITIS C VIRUS (HCV)-INFECTED BLOOD-DONORS BY A MULTIPLE-ANTIGEN HCV ENZYME-IMMUNOASSAY [J].
KLEINMAN, S ;
ALTER, H ;
BUSCH, M ;
HOLLAND, P ;
TEGTMEIER, G ;
NELLES, M ;
LEE, S ;
PAGE, E ;
WILBER, J ;
POLITO, A .
TRANSFUSION, 1992, 32 (09) :805-813
[5]   Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention [J].
Lavanchy, D. .
JOURNAL OF CLINICAL VIROLOGY, 2005, 34 :S1-S3
[6]   A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation [J].
Li, Chunfu ;
Wu, Xuedong ;
Feng, Xiaoqing ;
He, Yuelin ;
Liu, Huaying ;
Pei, Fuyu ;
Liao, Jianyu ;
He, Lan ;
Shi, Lei ;
Li, Na ;
Liu, Qiujun ;
Liu, Shiting ;
Chen, Geyu ;
Su, Qingxia ;
Ren, Yuqiong ;
Wang, Yanhua ;
Tan, Wanxia .
BLOOD, 2012, 120 (19) :3875-3881
[7]  
Mahfooz ur Rahman, 2003, Pakistan Journal of Medical Sciences, V19, P161
[8]   Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study [J].
Pasricha, Sant-Rayn ;
Frazer, David M. ;
Bowden, Donald K. ;
Anderson, Gregory J. .
BLOOD, 2013, 122 (01) :124-133
[9]   THALASSEMIA-MAJOR 1995 - OLDER PATIENTS, NEW THERAPIES [J].
RUND, D ;
RACHMILEWITZ, E .
BLOOD REVIEWS, 1995, 9 (01) :25-32
[10]  
Shah Neeraj, 2010, Asian J Transfus Sci, V4, P94, DOI 10.4103/0973-6247.67029